Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences ; volume:17 ; number:1 ; day:23 ; month:1 ; year:2017 ; pages:1-14 ; date:12.2017
BMC health services research ; 17, Heft 1 (23.1.2017), 1-14, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Lanitis, Tereza
- Contributor
-
Leipold, Robert
Hamilton, Melissa
Rublee, Dale
Quon, Peter
Browne, Chantelle
Cohen, Alexander T.
SpringerLink (Online service)
- DOI
-
10.1186/s12913-017-1995-8
- URN
-
urn:nbn:de:1111-201703014601
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lanitis, Tereza
- Leipold, Robert
- Hamilton, Melissa
- Rublee, Dale
- Quon, Peter
- Browne, Chantelle
- Cohen, Alexander T.
- SpringerLink (Online service)
Other Objects (12)
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Two Late Recurrences of Conjunctival Melanoma
On the growth of multi-recurrences
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
Determination of the non-vitamin K antagonist oral anticoagulants apixaban and dabigatran in plasma, serum and urine samples
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Two Late Recurrences of Conjunctival Melanoma
On the growth of multi-recurrences
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
Determination of the non-vitamin K antagonist oral anticoagulants apixaban and dabigatran in plasma, serum and urine samples
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
Two Late Recurrences of Conjunctival Melanoma
On the growth of multi-recurrences
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
Determination of the non-vitamin K antagonist oral anticoagulants apixaban and dabigatran in plasma, serum and urine samples